B · Normal
September 12th: AstraZeneca’s Etcamah failed to meet the primary progression-free survival endpoint in the SERENA-4 trial.
Related telegraphs
On September 22, the Philadelphia Semiconductor Index expanded to 1%, reporting
09-22 22:28
On September 22, Microsoft’s Xbox division is undergoing a new round of layoffs
09-22 22:25
On September 22, the S&P 500 Financial Sector Index fell 1.5%, hitting its lowes
09-22 22:19
On September 22, the Nasdaq 100 index expanded to 0.6% and is expected to close
09-22 22:14
[U.S. stock cloud computing service provider sector rises] On September 22, the
09-22 21:55
[SanDisk stock price stands above $1,900] On September 22, SanDisk’s stock price
09-22 21:55
Comments